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Introduction: The physical properties of proton beam radiation 
may offer advantages for treating patients with non–small-cell lung 
cancer (NSCLC). However, its utility for the treatment of medically 
inoperable stage I NSCLC patients with stereotactic body radiation 
therapy (SBRT) is unknown.
Methods: outcomes for patients with medically inoperable stage 
I NSCLC treated with proton SBRT were retrospectively analyzed. 
Proton SBRT was selected as the treatment modality based on pul-
monary comorbidities (n = 5), prior chest radiation or/and multiple 
primary tumors (n = 7), or other reasons (n = 3). Treatments were 
administered using 2 to 3 proton beams. Treatment toxicity was 
scored according to common toxicity criteria for adverse events ver-
sion 4 criteria.
Results: Fifteen consecutive patients and 20 tumors were treated with 
proton SBRT to 42 to 50 Gy(relative biological effectiveness) in 3 to 
5 fractions between July 2008 and September 2010. Treatments were 
well tolerated with only one case of grade 2 fatigue, one case of grade 
2 dermatitis, three cases of rib fracture (maximum grade 2), and one 
case of grade 3 pneumonitis in a patient with severe chronic obstruc-
tive pulmonary disease. With a median follow-up of 24.1 months, 
2-year overall survival and local control rates were 64% (95% confi-
dence limits, 34%–83%) and 100% (83%–100%), respectively.
Conclusions: We conclude that proton SBRT is effective and well 
tolerated in this unfavorable group of patients. Prospective clini-
cal trials testing the utility of proton SBRT in stage I NSCLC are 
warranted.
Key Words: Stereotactic body radiation therapy, Proton therapy, 
Non–small-cell lung cancer.
(J Thorac Oncol. 2012;7: 1021–1025)
Stereotactic body radiation therapy (SBRT), or stereotactic ablative body radiotherapy (SABR), is a specialized type 
of radiation therapy characterized by a higher (“ablative”) 
dose per fraction compared to conventional fractionated 
radiation therapy, a highly conformal dose distribution with 
a sharp dose gradient between tumor and normal tissues, and 
measures that ensure precise radiation delivery such as daily 
image guidance, fiducial tracking, or stereotactic body frame 
use. SBRT with 3 to 5 fractions has emerged as a standard 
therapy for medically inoperable patients with peripherally 
located stage I non–small-cell lung cancer (NSCLC).1,2
However, there are several clinical settings in which the 
therapeutic benefit of photon radiation based SBRT might be 
limited, including the treatment of centrally located tumors, 
tumors close to the chest wall, and large tumors (greater than 
or equal to 5 cm).3,4 In addition, the utility of SBRT in patients 
with poor lung function (defined as forced expiratory volume 
in 1 second <50%, diffusing capacity of the lung for carbon 
monoxide <40% of predicted, or oxygen dependence),5 mul-
tiple primary tumors, and prior chest radiation therapy has not 
been established. In these scenarios, the use of proton beam 
radiation may be beneficial for normal tissue sparing because 
proton beams have no exit dose and high conformality can 
be achieved with 2 to 3 beams instead of the 7 to 10 beams 
usually employed for photon SBRT. As a result, there is a sig-
nificantly reduced low-dose bath with protons compared to 
photons, thereby allowing sparing of nontargeted organs such 
as uninvolved lung and heart.
Excellent outcomes for hypofractionated proton therapy 
in early-stage NSCLC have been reported, however the treat-
ment courses were still protracted by modern SBRT standards 
spanning 10 to 35 fractions.6–8 Theoretical dosimetric stud-
ies have shown that proton radiation can reduce the integral 
dose to normal lung consistent with the idea that patients with 
poor lung function may tolerate proton SBRT but not photon 
SBRT.9–11 However, the beam characteristics of proton therapy 
also result in a more homogeneous dose distribution, com-
pared to photon SBRT where doses are typically prescribed 
to isodose lines of ~70% to 80%, raising the possibility of 
lower tumor control rates because of the lack of hotspots in 
the tumor center. Here, we report the outcomes for the first 15 
consecutive patients treated with proton SBRT at the Francis 
H. Burr Therapy Center at Massachusetts General Hospital, 
which we believe is the first published cohort of patients 
treated in this fashion.
METHODS
Patient Selection
Patients with clinical stage I NSCLC were treated 
with proton SBRT between July 2008 and September 2010. 
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All consecutively treated patients in this time period were 
included in the current analysis. Patients typically had severe 
chronic obstructive pulmonary disease (CoPD) or interstitial 
lung disease, multiple primary tumors, and/or prior radiation 
to the chest (Table 1). No reirradiation cases (failure in a prior 
irradiated site) were included. All patients were staged by pos-
itron emission tomography/computed tomography (CT) at the 
time of diagnosis. A retrospective database was constructed 
using the electronic medical record and by extracting data 
from the treatment planning system. An Institutional Review 
Board approved the current study.
Simulation and Treatment Planning
Patients were positioned supine on a wing board and 
asked to breathe freely while undergoing four-dimensional CT 
imaging without intravenous contrast and respiratory monitor-
ing using the real time positioning management system from 
Varian Medical Systems. Image contouring was performed on 
2.5 mm CT slices using the AdvantageSim MD version 4.4 
(GE Healthcare Systems, Waukesha, WI). Gross target vol-
ume (GTV) delineation was typically performed on the 30% 
phase CT set according to the mid-ventilation approach.12 No 
margin was added for microscopic disease.
Proton treatment plans were created by CMS Xio (ver-
sion 4.2, Maryland Heights, Mo) following our published 
approach.12,13 Treatments were designed with 2 to 3 passively 
scattered coplanar beams, depending on tumor size and loca-
tion of the tumor. For each beam, the 95% isodose line was 
chosen to conform around the GTV before applying aperture 
expansion and range compensator smearing to account for 
setup error (5 mm) and individual respiratory motion. Because 
of range uncertainty, 3.5% + 2 mm of the proximal and distal 
ranges were added as margin proximally and distally to the 
GTV.
Target doses and organs at risk dose constraints were 
adapted from Radiation Therapy oncology Group protocols.14 
Fractionation was chosen so that a biological effective dose 
of at least 100 Gy(relative biological effectiveness [RBE]) to 
the tumor was achieved.15 The RBE factor for proton planning 
was 1.1.
Radiation Treatment
Treatments were delivered at the Francis H. Burr Proton 
Therapy Center. The accuracy of SBRT with protons requires 
dosimetric and geometric accuracy as established and con-
firmed through various quality assurance (QA) procedures. 
Dosimetry of proton fields in our system has been well estab-
lished with an accurate dosimetry prediction model16 and is 
maintained by a weekly QA procedure to track the stability 
of the model parameters. Weekly QA also tracks stability of 
range better than ±0.5 mm. The lung geometry is particularly 
complex for proton treatments as a consequence of the large 
tissue inhomogeneities. overall dosimetry accuracy in patient 
is therefore verified by Monte Carlo calculations17 and con-
firms the applicability of our dose algorithm in patient in this 
complex anatomy.
Daily treatment verification relies on geometric repo-
sitioning of the patient using the Digital Imaging Position 
System. Dual orthogonal X-rays and treatment portals for each 
field were taken before treatment to match multiple bony land-
marks to digitally reconstructed radiographs from the plan-
ning CT. All fields were treated every day. Total treatment time 
for each fraction was routinely 20 to 25 minutes. Treatments 
were given on consecutive weekdays, 24 hours apart.
Follow-Up
Follow-up began on the day of completion of proton 
therapy and continued until last observation or death through 
September of 2011. Follow-up consisted of evaluations 4 to 6 
weeks after the completion of radiation treatment and every 3 
to 4 months for 2 years, and every 6 months thereafter. Each 
evaluation consisted of a complete history and physical and a 
diagnostic chest CT. Pulmonary function tests and PET scans 
were obtained as clinically indicated. Local failure was defined 
as a 20% increase in the longest tumor diameter on CT scan 
and either biopsy confirmation of recurrence or associated 
fluorodeoxyglucose avidity on two consecutive PET scans that 
was of similar intensity as on the pretreatment staging scan. 
Regional failure was defined as intralobar relapse outside of 
a 2 cm margin around the GTV or in the hilar, mediastinal, 
or supraclavicular lymph nodes. Distant failure was defined 
as intrathoracic relapse elsewhere or hematogenous spread. 
Toxicity grading was according to the common toxicity crite-
ria for adverse events v4.03. Grading for chest wall pain was 
adapted from the common toxicity criteria for adverse events 
criteria for general pain.
Statistical Methods
Time to overall survival and regional, distant, and local 
failure was assessed from the date of completion of radiation 
therapy. Local failure was defined as recurrence within 2 cm 
of the treated GTV. Regional failure was defined as lymph 
node recurrence within the hilum, mediastinum, supraclavicu-
lar fossa or as intralobar recurrence distant to the treated GTV. 
The method of Kaplan and Meier was used to estimate and 
characterize all cause mortality and regional, distant, and 
local failure.18 Analysis was performed with GraphPad Prism, 
Version 5.04 (GraphPad Software, Inc., La Jolla, CA).
RESULTS
The median age was 78 years (range, 62–89) and six of 
the 15 patients (40%) had an Eastern Cooperative oncology 
Group performance status of 2 to 3 (Table 1). Severe CoPD or 
interstitial lung disease was present in eight patients and five 
patients had at least two primary tumors. In five cases, prior tho-
racic radiation therapy, and in one case central location of the 
tumor, were also factors in the selection of protons as treatment 
modality. The median tumor size was 15 mm (range, 10–31 
mm) (Table 2). Four patients did not undergo biopsy because 
they either refused or were judged to be at unacceptably high 
procedural risk. Bronchoscopy or mediastinoscopy to assess 
nodal stations were not performed in any patients before SBRT. 
Eleven tumors were within 1 cm of the chest wall, and two were 
within 2 cm of the mediastinal pleura. The average respiratory 
tumor motion was 2 mm (range, 0–10 mm).
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The median total dose was 45 Gy(RBE) (range, 42–50 
Gy(RBE)) and the median fraction size was 14 Gy(RBE) 
(range, 10–16 Gy(RBE)) corresponding to a biological effec-
tive dose 10 of at least 100 Gy(RBE). The number of fractions 
was 3 for 17 out of 20 tumors. Four patients were treated with 
two or more courses of therapy, each for separate and distinct 
tumors (Table 1). The average V5 and V20 for the ipsilateral 
lung for these patients were 20.5% (range, 5%–39%) and 
9.5% (range, 2%–27%), respectively. The ipsilateral mean 
lung dose was 5.12 Gy(RBE) (range, 1.37–12.56). The con-
tralateral lung in all cases received no dose because of the lack 
of exit dose of protons. An example dose distribution is shown 
in Figure 1A. one patient had a pacemaker at the same level as 
his lung lesion and dose to this area was avoided by employing 
only two beams (see Fig. 1B).
Treatments were well tolerated with only one case of 
grade 2 dermatitis (Table 3). There was one case of grade 3 
pneumonitis in a patient with severe CoPD which responded 
to prednisone. This patient had an ipsilateral mean lung dose 
of 3.36 Gy(RBE). one patient had a symptomatic rib frac-
ture and two had asymptomatic fractures. For these patients, 
chest wall V30 and maximum doses were 11.1–24.9 cc and 
44.3–48.6 Gy(RBE), respectively. No grade 4 or 5 toxicities 
were observed.
There were six deaths (Table 1). of these, two were 
attributable to lung cancer progression whereas the other four 
were because of other causes. Two patients developed both 
regional and distant metastases, one developed only regional 
metastases, and one developed only distant metastases. No 
local failures within the radiation field were observed. With a 
TABLE 1. Patient Characteristics (n = 15)















1 CoPD, oxygen dependence 70 M 2 80 24/42 4–6 Lung 2 Pneumonia
2 CoPD, prior chest RT, 
multiple primary tumors
82 F 2 47 55/37 2 Lung, breast 2 Alive
3 CoPD 73 F 2 22 38/22 3 Lung 1 Alive
4 CoPD, SLE, prior chest RT 66 F 1 50 N/A 0 Lung 1 Lung cancer
5 CoPD, multiple primary 
tumors
80 F 2 100 62/29 2a Lung, breast 3 Alive
6 CoPD 86 M 1 30 45/25 0 Colon, AML 1 AML
7 ILD, CoPD 82 F 1 80 99/34 0 — 1 Alive
8 Adjacent ICD/pacemaker 79 M 0 40 56/62 0 — 1 Cardiac
9 CoPD, S/P intubation 63 F 2 80 N/A 0 — 1 Alive
10 Prior chest RT, multiple 
primary tumors
79 F 1 30 N/A 0 — 1 Alive
11 Prior chest RT, multiple 
primary tumors
70 F 1 150 97/74 0 Lung, NHL 1 Respiratory
12 Prior chest RT 62 F 1 60 19/N/A 0 Lung, larynx 1 Lung cancer
13 Central tumor, poor PS 72 F 3 0 N/A 0 — 1 Alive
14 N/A 89 F 1 25 N/A 0 Breast 1 Alive
15 Two ipsilateral primary 
tumors
78 F 1 50 N/A 0 Lung 2 Alive
aWith ambulation.
FEV1, forced expiratory volume in 1 second; DLCo, diffusing capacity of the lung for carbon monoxide; SBRT, stereotactic body radiation therapy; CoPD, chronic obstructive 
pulmonary disease; RT, radiation therapy; ILD, interstitial lung disease; ICD, internal cardiac defibrillator; S/P, status post; M, male, F, female; PS, ECoG performance status; N/A, not 
available; AML, Acute myeloid leukemia; NHL, Non Hodgkin Lymphoma; SBRT, Stereotactic Body Radiation Therapy; SLE, systemic lupus erythematosus.
TABLE 2. Tumor Characteristics (n = 20)
Characteristic n (%)
AJCC T-Stage
 T1a (≤2 cm) 16 (80)
 T1b (>2–3 cm) 2 (10)
 T2a (>3–5 cm) 2 (10)
Location
 Right 11 (55)
 Left 9 (45)
Lobe
 Upper 13 (65)
 Middle 4 (20)
 Lower 3 (15)
Histology
 Adenocarcinoma 9
 NSCLC NoS 4
 Squamous cell carcinoma 3
 No biopsy 4
Distance to chest wall
 ≤10 mm 11 (55)
 >10 mm 9 (45)
Distance to proximal bronchial tree  
or mediastinal pleura
 ≤20 mm 2 (10)
 >20 mm 18 (90)
Respiratory tumor motion, peak to peak
 >5 mm 2 (10)
AJCC, American Joint Committee on Cancer; NSCLC NoS, Non–small-cell lung 
cancer not otherwise specified.
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median follow-up time of 24.1 months, 2-year Kaplan Meier 
estimates of overall survival, local control, regional con-
trol, and distant control were 64% (95% confidence limits, 
34%–83%), 100% (83%–100%), 78% (38%–93%), and 86% 
(56%–95%), respectively. Three patients developed metachro-
nous primary tumors.
DISCUSSION
There is great interest in testing the utility of proton 
beam radiation in patients with both locally advanced stage III 
disease and early-stage NSCLC.8,19 Although standard photon 
SBRT achieves excellent local tumor control with low toxicity 
in the majority of patients of stage I patients, proton SBRT 
may be advantageous in cases that involve central tumors, 
tumors located close to the chest wall, multiple tumors, previ-
ous chest irradiation, and poor pulmonary function.
To this end, we find that proton SBRT was well tolerated in a 
cohort of patients with adverse factors such as pulmonary comor-
bidities, prior chest irradiation, or multiple primary tumors (80% 
of cases) (Table 1). In general, CoPD and larger low dose regions 
have been correlated with higher rates of radiation pneumonitis.20–22 
We hypothesize that the low pulmonary toxicity seen in our study 
may be a result of lower integral dose to surrounding lung because 
of the unique properties of protons and the use of only 2 to 3 beams. 
Notably, we only observed one case of grade 2 dermatitis even 
though protons are typically associated with higher skin doses. 
A recently reported proton dose escalation trial from the M.D. 
Anderson Cancer Center administered 87.5 Gy(RBE) at 
2.5 Gy(RBE)/fraction for stage I NSCLC, which was associ-
ated with grade 2 and 3 dermatitis in 67% and 17% of patients, 
respectively.8 our results are similar to the dermatitis rate seen 
in the Radiation Therapy oncology Group 0236 trial of pho-
ton SBRT where 7% of patients developed grade 2 or higher 
dermatitis.23
It is also noteworthy that we did not observe any local 
recurrence with a median follow-up of approximately 2 years, 
even though proton radiation is not associated with the typi-
cal large intratumoral hostpots that are produced by photon 
SBRT. Prior dosimetric comparisons of proton and photon 
SBRT have generally shown that target coverage is similar 
between both techniques, although with more generous allow-
ances for range uncertainty the conformity index for protons 
can be larger.3,11 It should be noted that most tumors in our 
cohort were located in the upper lobes and tumor motion was 
therefore low (average of 2 mm) and resulting in less addi-
tional margin around the GTV.
In conclusion, this clinical experience with proton 
SBRT may be regarded as an important preliminary confirma-
tion of the theoretical advantages of proton beam radiation that 
have been highlighted by several groups.3,9–11 We hypothesize 
that in appropriate clinical settings proton SBRT has the poten-
tial for normal tissue sparing that cannot be achieved with 
conformal photon techniques. In addition, for larger tumors 
particular in difficult locations, protons may allow for escala-
tion of dose to levels that cannot be safely achieved with pho-
tons. Prospective clinical trials testing the safety and efficacy of 
proton SBRT in comparison to photon SBRT are warranted.
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FIGURE 1. Sample proton stereot-
actic body radiation therapy dose 
distributions. A, Limitation of dose to 
central structures. Radiation dose to 
the right bronchial tree (yellow) was 
limited by using a two-beam arrange-
ment. The dose falloff of the anterior 
beam results in a relatively small dose 
deposition for the major airways 
immediately posterior. B, Limitation 
of dose to a pace maker/defibrillator. 
A similar strategy to that shown in 
(A) was used to limit dose to a pace-
maker, only in this case dose falloff of 
a posterior beam was critical.
TABLE 3. Radiation Associated Toxicity (n = 20)
Graded Toxicity Grade 1 Grade 2 Grade 3
Chest wall pain 0 1 0
Dermatitis 3 1 0
Dyspnea 0 0 0
Fatigue 1 1 0
Pneumonitis 6 0 1
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